TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34543098

Group type: EXPERIMENTAL
Intervention: 600 mg daily dose of linezolid
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 300 mg daily dose of linezolid
Number of subjects: 124
Study: 36190041

Group type: EXPERIMENTAL
Intervention: Ocular viscoelastic device (OVD) group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 33814474

Group type: EXPERIMENTAL
Intervention: EMG BF training combined with conventional physical therapy (n=17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional physical therapy (Control group, n=16)
Number of subjects: 33
Study: 32807615

Group type: EXPERIMENTAL
Intervention: One-stage lateral thoracodorsal flap with an implant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-stage expander reconstruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latissimus dorsi reconstruction combined with an implant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deep inferior epigastric artery perforator (DIEP) reconstruction
Number of subjects: 0
Study: 32880468

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy or chemoradiotherapy
Number of subjects: 2173

Group type: COMPARATOR
Intervention: Standard pathological evaluation according to the Leeds protocol
Number of subjects: 2173

Group type: COMPARATOR
Intervention: Up-front resection with adjuvant chemotherapy
Number of subjects: 2173
Study: 33026636

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 18
Study: 33047216

Group type: EXPERIMENTAL
Intervention: Cemdisiran (50–900 mg single doses or 100–600 mg repeat doses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cemdisiran (200 or 400 mg weekly)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Eculizumab (900 or 1200 mg biweekly)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cemdisiran (600 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cemdisiran (various doses)
Number of subjects: 32
Study: 33394852

Group type: EXPERIMENTAL
Intervention: Paxos Scope (smartphone-based ophthalmic camera)
Number of subjects: 467
Study: 32393307

Group type: EXPERIMENTAL
Intervention: Usual care plus the offer of an additional preventive care consultation with the specialist clinician (occupational therapist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36116675

Group type: EXPERIMENTAL
Intervention: Gastric conditioning (GC) before surgery
Number of subjects: 38

Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Successful gastric conditioning (GC)
Number of subjects: 38
Study: 33885775

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (800 mg loading dose, then 400 mg daily for 9 days)
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (800 mg and 200 mg loading dose every 12 hours, followed by 400 mg and 100 mg every 12 hours for 9 days)
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 685
Study: 34505548

Group type: EXPERIMENTAL
Intervention: Device dropper (DD) method
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional drop instillation (CDI) method
Number of subjects: 72
Study: 33504185

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 35940954

Group type: EXPERIMENTAL
Intervention: Oculus GO VR goggles
Number of subjects: 29

Group type: COMPARATOR
Intervention: No VR goggles
Number of subjects: 29
Study: 33907242

Group type: EXPERIMENTAL
Intervention: Low serum alpha‐klotho concentration
Number of subjects: 103
Study: 32452588

Group type: EXPERIMENTAL
Intervention: PBI-05204
Number of subjects: 42
Study: 33866856

Group type: EXPERIMENTAL
Intervention: Top 3 cost categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top 5 cost categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All cost components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental therapies
Number of subjects: 0
Study: 33012605

Group type: EXPERIMENTAL
Intervention: BK-SE36/CpG (full-dose)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BK-SE36/CpG (half-dose)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study: 33032885

Group type: EXPERIMENTAL
Intervention: Finger Kazoo Intensive Short-Term Vocal Therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 32258112

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (wellness education program)
Number of subjects: 46
Study: 34797597

Group type: EXPERIMENTAL
Intervention: Intralesional injection of tranexamic acid
Number of subjects: 43

Group type: COMPARATOR
Intervention: Topical application of Kligman combination drug
Number of subjects: 43
Study: 34548284

Group type: EXPERIMENTAL
Intervention: Intensive therapy (mean HbA1c 7.2%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (mean HbA1c 9.0%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DCCT intensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: DCCT conventional therapy
Number of subjects: 0
Study: 33964415

Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants who smoked >1 pack per day
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants who underwent their first LCS scan
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with an associates degree
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with a bachelor's degree
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with some worry about lung cancer
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with a benign screening result
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Smoking cessation trial participants with a probably benign screening result
Number of subjects: 926
Study: 36416841

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 international units daily)
Number of subjects: 2083

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2083
Study: 33360047

Group type: EXPERIMENTAL
Intervention: Metformin (1 g/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 32993628

Group type: EXPERIMENTAL
Intervention: Education reinforcing practice guidelines with manufacturer-prepared pre-filled flush syringes.
Number of subjects: 619

Group type: COMPARATOR
Intervention: Standard care with manually prepared flushes of 0.9% sodium chloride (control group).
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Intervention group (education and guidelines).
Number of subjects: 619
Study: 36161344

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (700 IU) plus Calcium (500 mg) daily for 3 years
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo (double placebo) daily for 3 years
Number of subjects: 386
Study: 34628916

Group type: EXPERIMENTAL
Intervention: Sitting and lying Liuzijue exercise (LG) for 3 months, 30 minutes twice daily.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment and nursing (CG)
Number of subjects: 80
Study: 32059477

Group type: EXPERIMENTAL
Intervention: Rigorous, self-monitored, lifestyle modification program (intervention group, IG) for 12 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: General advice (GA)
Number of subjects: 300
Study: 35689818

Group type: EXPERIMENTAL
Intervention: Oral sulphate tablets (OST)
Number of subjects: 110
Study: 35896217

Group type: EXPERIMENTAL
Intervention: 2.4-mm cryoprobe
Number of subjects: 89

Group type: COMPARATOR
Intervention: 1.9-mm cryoprobe
Number of subjects: 89

Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 89
Study: 33849367

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D, 1 μg/kg before, and 0.6 μg/kg/hour during procedure)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Midazolam (Group M, 2 mg before procedure)
Number of subjects: 197
Study: 32960773

Group type: EXPERIMENTAL
Intervention: Digital devices for information delivery (tablet computers, e-learning platforms, public website)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital devices for information delivery
Number of subjects: 0
Study: 34032356

Group type: EXPERIMENTAL
Intervention: Experts by Experience participation in mental health nursing education
Number of subjects: 0
Study: 36437019

Group type: EXPERIMENTAL
Intervention: Salt-reduction programs for children engaging families and teachers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational song with interesting sounds and lyrics as BGM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-monitoring of salt intake using a versatile salinity meter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional education for the elderly over three months
Number of subjects: 0
Study: 33231313

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 6
Study: 35480138

Group type: EXPERIMENTAL
Intervention: Bevacizumab, gemcitabine, and cisplatin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gemcitabine combined with cisplatin
Number of subjects: 100
Study: 35328977

Group type: EXPERIMENTAL
Intervention: VR FestLab (intervention group)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Oculus Quest—First Steps (control group)
Number of subjects: 372
Study: 34852983

Group type: EXPERIMENTAL
Intervention: Prediction model for risk of seizure recurrence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prediction model for risk of seizure recurrence (recalibrated)
Number of subjects: 0
Study: 32779459

Group type: EXPERIMENTAL
Intervention: PF tafluprost/timolol FC
Number of subjects: 87
Study: 35770524

Group type: EXPERIMENTAL
Intervention: Multi-set, high-load resistance exercise in hypoxia (inspiratory oxygen fraction = 0.145)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Multi-set, high-load resistance exercise in hypoxia
Number of subjects: 8

Group type: COMPARATOR
Intervention: Multi-set, high-load resistance exercise in hypoxia and normoxia
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maximal isometric bench press trials after a 10-min hypoxic priming period
Number of subjects: 8
Study: 33586513

Group type: EXPERIMENTAL
Intervention: G + chemo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ra + chemo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rp + chemo
Number of subjects: 0
Study: 35015065

Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (5 weekly sessions)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (12 twice-weekly sessions)
Number of subjects: 169
Study: 33250456

Group type: EXPERIMENTAL
Intervention: Ergonomic workstation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 35900305

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fractional microneedle radiofrequency (FMR)
Number of subjects: 20
Study: 34630934

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE; 16 sessions in 16 weeks)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intensified Prolonged Exposure (iPE; 12 sessions in 4 weeks followed by 2 booster sessions)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: STAIR+Prolonged Exposure (STAIR+PE; 8 sessions of STAIR followed by 8 sessions of PE)
Number of subjects: 149
Study: 34505829

Group type: COMPARATOR
Intervention: Placebo control in surgical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASPIRE guidelines
Number of subjects: 0
Study: 32552627

Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry assays in patients with primary sclerosing cholangitis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rotational thromboelastometry assays in patients with nonbiliary causes of cirrhosis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrinsic assay in patients with primary sclerosing cholangitis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intrinsic assay in patients with nonbiliary causes of cirrhosis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall coagulation indexes in patients with primary sclerosing cholangitis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Overall coagulation indexes in patients with nonbiliary causes of cirrhosis
Number of subjects: 80
Study: 35604680

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33687375

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (TM)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 201
Study: 32016500

Group type: COMPARATOR
Intervention: Conventional hump resection technique (Group A)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Push-down procedure (Group B)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Let-down procedure (Group C)
Number of subjects: 6
Study: 35575603

Group type: EXPERIMENTAL
Intervention: The Connection Project (experiential, relationship‐focused intervention)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 438
Study: 33694072

Group type: EXPERIMENTAL
Intervention: Coordinated case management across medical, mental health, and social service organizations (n = 486)
Number of subjects: 895

Group type: COMPARATOR
Intervention: Usual care (n = 409)
Number of subjects: 895
Study: 35180287

Group type: EXPERIMENTAL
Intervention: Intensive exercise intervention (two daily sessions of moderate-intensity exercises)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Intensive exercise intervention
Number of subjects: 323
Study: 34164887

Group type: EXPERIMENTAL
Intervention: Ato‐Oxy plus zolpidem (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ato‐Oxy plus placebo
Number of subjects: 12
Study: 32709645

Group type: EXPERIMENTAL
Intervention: Nutritionally modified infant formula
Number of subjects: 1923

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 1923
Study: 36251422

Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin System Inhibitors (RASi)
Number of subjects: 7174

Group type: COMPARATOR
Intervention: Calcium channel blocker or thiazide diuretic (control)
Number of subjects: 7174
Study: 35763114

Group type: EXPERIMENTAL
Intervention: Amifampridine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 34560015

Group type: EXPERIMENTAL
Intervention: PXL770 250 mg once daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PXL770 250 mg twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PXL770 500 mg once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 120
Study: 32863275

Group type: EXPERIMENTAL
Intervention: Robotic hysterectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 50
Study: 36314868

Group type: EXPERIMENTAL
Intervention: LHF-535 (0.3 mg/kg to 40 mg/kg single ascending dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: LHF-535 (450 mg/day, 900 mg/day, 1,125 mg/day for 14 days, with a loading dose of 2,250 mg for the first dose in the 1,125 mg/day cohort)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 34102807

Group type: EXPERIMENTAL
Intervention: HMS Plus
Number of subjects: 188

Group type: COMPARATOR
Intervention: ACT Plus
Number of subjects: 188
Study: 32366280

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study: 36031789

Group type: EXPERIMENTAL
Intervention: Dolutegravir-based therapy
Number of subjects: 464
Study: 35130224

Group type: EXPERIMENTAL
Intervention: Aescin
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 35536489

Group type: EXPERIMENTAL
Intervention: High-intensity training with Bryndza cheese
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-intensity training without Bryndza cheese
Number of subjects: 24
Study: 32650771

Group type: EXPERIMENTAL
Intervention: Digital integrated healthcare platform with continuous glucose monitoring and feedback from medical staff (Experimental group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital integrated healthcare platform by themselves without feedback (Experimental group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine diabetes care (Control group A)
Number of subjects: 0
Study: 34074945

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 521
Study: 33920232

Group type: EXPERIMENTAL
Intervention: AREDS formulation with added DHA, lutein, zeaxanthin, resveratrol, and hydroxytyrosol (intervention group)
Number of subjects: 109

Group type: COMPARATOR
Intervention: AREDS formulation (control group)
Number of subjects: 109
Study: 33020152

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 580
Study: 36273651

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 100mg, 2ml
Number of subjects: 130

Group type: COMPARATOR
Intervention: Adrenaline 0.2mg, 2ml (1:10000)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both TXA and adrenaline
Number of subjects: 130
Study: 33223487

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study: 33846152

Group type: EXPERIMENTAL
Intervention: Core outcome set defined through a Delphi process involving surgical and non-surgical stakeholders
Number of subjects: 0
Study: 34601160

Group type: EXPERIMENTAL
Intervention: TXA plus topical CSS
Number of subjects: 150

Group type: COMPARATOR
Intervention: TXA only
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 33823461

Group type: EXPERIMENTAL
Intervention: Baseline WMHv (1.62 mL median, IQR 0.66–3.98 mL)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Log-transformed WMHv
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Highest quartile of WMHv
Number of subjects: 717
Study: 32742143

Group type: EXPERIMENTAL
Intervention: Group cessation intervention plus pharmacotherapy
Number of subjects: 347
Study: 34036434

Group type: EXPERIMENTAL
Intervention: 7.5% HX‐BGC
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride (NaF)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 35081762

Group type: EXPERIMENTAL
Intervention: GE + TN
Number of subjects: 504

Group type: COMPARATOR
Intervention: GE
Number of subjects: 504
Study: 34676656

Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) applied twice a week for six consecutive weeks in addition to standard wound care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard wound care
Number of subjects: 20
Study: 32450497

Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 or 4 mg/day
Number of subjects: 38
Study: 35449322

Group type: EXPERIMENTAL
Intervention: Citrate-free formulation of ixekizumab (1 mL SC injection)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Commercial formulation of ixekizumab (1 mL SC injection)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Citrate-free formulation of ixekizumab (80 mg single SC injection)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Commercial formulation of ixekizumab (80 mg single SC injection)
Number of subjects: 315
Study: 32396902

Group type: EXPERIMENTAL
Intervention: Self-sampled specimens
Number of subjects: 300

Group type: COMPARATOR
Intervention: Physician-sampled specimens
Number of subjects: 300
Study: 36463592

Group type: EXPERIMENTAL
Intervention: Educational program for clinical educators (e-learning and seminar)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 77
Study: 32875421

Group type: EXPERIMENTAL
Intervention: Surgical drains
Number of subjects: 584

Group type: COMPARATOR
Intervention: No surgical drains
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Prolonged drain removal (after postoperative day 13)
Number of subjects: 584
Study: 32134309

Group type: EXPERIMENTAL
Intervention: Mandatory behavioral staff-training program consisting of didactic training followed by a written exam, and in vivo training and assessment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Completion of the staff-training program.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Written and in vivo test scores from staff training.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staff who disagreed with behavioral management principles.
Number of subjects: 0
Study: 36192924

Group type: EXPERIMENTAL
Intervention: Chinese Medical Nutrition Therapy (CMNT) diet for T2D patients (5-day low-calorie diet followed by 10 days of habitual eating for 90 days)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Chinese Medical Nutrition Therapy (CMNT) diet for db/db mice (low-calorie mouse CMNT diet in day 1-4 and ad libitum regular chow for up to 7 days per cycle)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (normal diet for T2D patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (ad libitum access to regular chow for db/db mice)
Number of subjects: 39
Study: 33721740

Group type: EXPERIMENTAL
Intervention: Harry Potter-based mental health literacy curriculum (3-month teacher-delivered intervention)
Number of subjects: 200
Study: 32293383

Group type: EXPERIMENTAL
Intervention: Positive Behaviour Support (PBS) delivered by health professionals
Number of subjects: 113

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Positive Behaviour Support (PBS)
Number of subjects: 113